Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Novacea — Merger or Acquisition (September 2008)

32 slides from Paratek Pharmaceuticals's merger presentation, Sep 2, 2008

  1. Slide 1: September 2008

    September 2008 September 2008 Exhibit 99.3

  2. Slide 2: Safe harbor statement

    Safe harbor statement Safe harbor statement This slide deck contains forward-looking statements that are based upon current expectations within the meaning of the Private Securities Reform Act of 1995. We intend that such statements be protected by the safe harbor created thereby. Forward-looking st

  3. Slide 3: Deriving new patient benefits from proven CNS drugs

    Deriving new patient benefits from proven CNS drugs – Enhanced performance and new indications – Known safety and efficacy profile from established parent compounds – Reduced risk development strategy – Proprietary products; significant market opportunities : low-dose sublingual zolpidem, MOTN insom

  4. Slide 4: Experienced management team

    Experienced management team Experienced management team Idenix, Novartis Susan Koppy, VP Corp Dev Peninsula Pharmaceuticals Sharon Sakai, PhD, Sr Dir Regulatory Alza Nipun Davar, PhD, VP Pharm Sci Abbott, Lorex, Sanofi F. Steinberg, DO, consulting CMO Montreux Equity Partners Thomas P. Soloway, CFO

  5. Slide 5: Intermezzo: low dose zolpidem for middle of the night insomnia

    Intermezzo ® Low dose zolpidem for middle of the night (MOTN) insomnia Proposed indication statement: “ Intermezzo (zolpidem tartrate sublingual lozenge) is indicated for the treatment of insomnia characterized by difficulty returning to sleep after awakening in the middle of the night”

  6. Slide 6: Rx insomnia therapeutics: a $4 billion market

    10% to 15% seek physician help (3) $1.4B 2002 to $5B 2010 (2) New understanding of insomnia leads to new products to million people (2) Insomnia market growth (‘07 over ‘06): 9% in demand (TRx), 5% in value (1) Rx insomnia therapeutics: a $4 billion market Rx insomnia therapeutics: a $4 billion mark

  7. Slide 7: Stanford Sleep Epidemiology Research Center: MOTN awakening, the #1 insomnia symptom

    Stanford Sleep Epidemiology Research Center: MOTN awakening: the #1 insomnia symptom Stanford Sleep Epidemiology Research Center: MOTN awakening: the #1 insomnia symptom Large scale population based sleep epidemiology study, ~9,000 subjects over 6 years – Ohayon MM: Nocturnal Awakenings and comorbid

  8. Slide 8: Phase 3 outpatient study: awakenings with at least 4 hours remaining in bed

    8-9pm 9-10pm 10- 11pm 11- 12am 12-1am 1-2am 2-3am 3-4am 4-5am 5-6am 6-7am All MOTN treatment calls MOTN calls with >=4 hours remaining in bed Phase 3 outpatient study n = 294 : outpatient study: 96% of > 5,000 awakenings had at least 4 hrs remaining in bed : outpatient study: 96% of > 5,000 awakenin

  9. Slide 9: MOTN awakenings typically occur not every night

    MOTN awakenings typically occur to nights per week (1) , not every night, even in severe chronic insomnia 8 hour sleep aids require bedtime prophylactic dosing before an awakening occurs The ideal therapeutic would be used only when and if a patient needs help returning to sleep, not every night Hyp

  10. Slide 10: Sleep lab clinical result: sleep onset with 3.5 mg dose

    Sleep lab clinical result: 14 minute sleep onset with 3.5 mg dose Patients reported greater next day alertness vs. placebo Sublingual lozenge dissolves in ~ 2 minutes pH driven free base zolpidem 72% dose reduction vs. the most commonly prescribed brand Used only when needed (1) Ohayon MM: Nocturnal

  11. Slide 11: Rapid bioavailability driven by Bimucoral technology

    Hydrophilic zolpidem (88%) Hydrophilic zolpidem (50%) Lipophilic zolp (12%) Lipophilic zolpidem (50%) Lipophilic zolpidem (~ 100%) Normal Saliva pH = ~6 pH = 6.9 (“pKa”) pH = 9.5 pH = pKa pH < pKa pH > pKa Bimucoral technology drives pH above pKa Rapid bioavailability driven by Bimucoral technology

  12. Slide 12: 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose

    3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose PK comparison study: Intermezzo 3.5mg vs. Ambien 10mg PO n=36 Time (min) 9.3x 2.9x 1.4x 3.5 mg Ambien 10 mg Intermezzo 3.5mg Ambien 10mg p.o.

  13. Slide 13: Intermezzo Phase 3 clinical results

    Intermezzo ® Phase 3 clinical results Phase 3 clinical results Low dose zolpidem for middle of the night (MOTN) insomnia

  14. Slide 14: Phase 3 sleep lab study (October 2006)

    : Phase 3 sleep lab study (October 2006) : Phase 3 sleep lab study (October 2006) Principal investigators: Thomas Roth, PhD and Martin Scharf, PhD Study design: Double-blind, placebo-controlled study for objective (PSG) evaluation of sleep-onset safety and efficacy of 1.75 mg and 3.5 mg after MOTN a

  15. Slide 15: Intermezzo achieved rapid sleep onset

    44.6 17.0 30.7 14.2 23.7 37.3 : achieved rapid sleep onset, even in subjects with baseline awakenings >60 minutes : achieved rapid sleep onset, even in subjects with baseline awakenings >60 minutes p<0.003 vs. placebo p<0.001 vs. placebo p<0.001 vs. placebo p<0.001 vs. placebo Placebo 1.75mg 3.5mg P

  16. Slide 16: Intermezzo put more patients back to sleep faster

    : put more patients back to sleep faster vs baseline or placebo : put more patients back to sleep faster vs baseline or placebo 75% 56% 28% Phase 3 Sleep Lab Study n = 82

  17. Slide 17: No reported hangover effects at 4 hrs vs placebo

    61.88 61.59 60.57 62.36 64.25 63.56 : No reported hangover effects at 4 hrs vs placebo : No reported hangover effects at 4 hrs vs placebo Objective (DSST) Subjective (VAS) p<0.62 vs. placebo p<0.15 vs. placebo p<0.44 vs. placebo p<0.91 vs. placebo Placebo 1.75mg 3.5mg

  18. Slide 18: Intermezzo helped patients feel better the next day

    Placebo 1.75mg 3.5mg helped patients feel better the next day helped patients feel better the next day p<0.001 vs. placebo p<0.001 vs. placebo p<0.017 vs. placebo p<0.024 vs. placebo p<0.009 vs. placebo “Good” or “Excellent” next day ratings NS Phase 3 Sleep Lab Study n = 82 Sleep Quality Refreshing

  19. Slide 19: Phase 3 outpatient study (January 2008)

    Principal investigators: Andrew Krystal, MD and Thomas Roth, PhD Study design: Randomized, double-blind, placebo controlled, outpatient study to evaluate the safety and efficacy of 3.5 mg for the prn treatment of insomnia after MOTN awakening Study population: 294 non-elderly primary insomnia patien

  20. Slide 20: Primary sleep onset endpoint confirmed in second Phase 3 study

    69.42 56.37 68.13 38.22 : primary sleep onset endpoint confirmed in second Phase 3 study : primary sleep onset endpoint confirmed in second Phase 3 study p<0.0001 vs. placebo Latency to Sleep Onset (LSO MOTN ) week average Phase 3 outpatient study n = 294 week treatment Baseline week treatment Basel

  21. Slide 21: Intermezzo achieved consistently faster sleep onset

    : achieved consistently faster sleep onset vs. placebo over the entire 4 week treatment period : achieved consistently faster sleep onset vs. placebo over the entire 4 week treatment period Latency to Sleep Onset (LSO MOTN ) weekly Phase 3 outpatient study n = 294 Placebo 3.5mg p<0.0001 vs. placebo

  22. Slide 22: Intermezzo produced ~30 minute improvement in sleep onset

    : produced ~30 minute improvement in sleep onset vs. baseline : produced ~30 minute improvement in sleep onset vs. baseline Latency to Sleep Onset (LSO MOTN ) improvement over baseline Phase 3 outpatient study n = 294 Placebo 3.5mg

  23. Slide 23: Patients reported next day effects better than placebo

    4.71 5.24 4.87 5.59 : reported next day effects better than placebo : reported next day effects better than placebo p<0.0041 vs. placebo Next day alertness 4 week average Phase 3 outpatient study n = 294 MORE ALERT MORE SLEEPY 4 week treatment Baseline 4 week treatment Baseline Placebo 3.5mg Baselin

  24. Slide 24: Average weekly treatment exposure

    Average weekly treatment exposure Phase 3 outpatient study n = 294 : no evidence of increased medication use during four week study : no evidence of increased medication use during four week study

  25. Slide 25: Intermezzo development timeline

    development timeline development timeline Ph 3: sleep lab FDA meeting Bridging PK Elderly PK Ph 3: outpatient 3.5 mg Fed/Fast Mfr. 300kg batch Swallowed PK/PD Pre NDA meeting Projected NDA submission Projected launch Complete Projected Q4 2008 H1 2010

  26. Slide 26: Intermezzo: Maximizing market potential

    Intermezzo ® : Maximizing market potential : Maximizing market potential

  27. Slide 27: Intermezzo commercialization strategy

    : commercialization strategy : commercialization strategy anticipated to be the first prn insomnia therapeutic specifically for treatment of middle of the night awakenings Key marketing factors – Insomnia direct to consumer advertising spending in decline: • Q1 08: Lunesta -42%, AmbienCR -33%, Rozer

  28. Slide 28: Intermezzo: Intellectual property

    Intermezzo ® : Intellectual property : Intellectual property

  29. Slide 29: Formulation and method of use patents pending

    : formulation and method of use patents pending in US and international markets : formulation and method of use patents pending in US and international markets Formulation for transmucosal absorption: – priority date of February 17, 2004 – low dose zolpidem (about 1mg to about 5 mg) – formulated wit

  30. Slide 30: Pipeline development

    Pipeline development Pipeline development

  31. Slide 31: Psychiatry pipeline product candidates

    TO-2060: – Fixed combination product: olanzapine / ondansetron – Successful proof of concept study in alcohol abusing patients – Active IND: April 2008 – Seeking NIAAA and/or corporate partner funding TO-2061: – Fixed combination product: risperidone / ondansetron – Obsessive compulsive disorder pil

  32. Slide 32: Registered trademark notice

    is a registered trademark of Transcept Pharmaceuticals, Inc.

Novacea — Merger or Acquisition (September 2008) on 6ix